Remicade as TNF Suppressor in Patients with Myelodysplastic Syndromes
- 1 October 2004
- journal article
- clinical trial
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 45 (10), 2099-2104
- https://doi.org/10.1080/10428190410001723322
Abstract
Remicade, a chimeric human-murine monoclonal antibody capable of neutralizing tumor necrosis factor alpha was given to 37 low-risk myelodysplastic syndromes (MDS) patients in two cohorts; 5 and 10 mg/kg intravenously every 4 weeks for 4 cycles. Median age was 68 years, 33 had primary MDS, 14 had refractory anemia (RA), 14 RA with ringed sideroblasts, 9 RA with excess blasts. Nine patients stopped therapy prior to completing 4 cycles, 3 from cohort 1 and 6 from cohort 2 and response was evaluated using the International Working Group criteria in 28 patients who completed the 4 cycles. Six patients showed disease progression, 14 had stable disease and 8 showed hematologic responses, 3/15 (20%) in cohort 1 and 5/13 (38%) in cohort 2. Two patients had multi-lineage responses, 2 had > 100% increase in absolute neutrophils, 1 had > 1 gm/dl increase in hemoglobin, 1 had reduction in blasts from 7% to 1%, and 2 had minor cytogenetic responses (> 50% reduction in + 8 and 20q-metaphases respectively). We conclude that Remicade may have a variety of activities in low risk MDS patients, is well tolerated with a high patient compliance, and may be considered for combination therapy in the future.Keywords
This publication has 4 references indexed in Scilit:
- Infliximab chimaeric anti‐tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromesBritish Journal of Haematology, 2002
- Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromesBlood, 2001
- Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromesLeukemia Research, 1996
- Apoptosis is a Common Histopathological Finding in Myelodysplasia: the Correlate of Ineffective HaematopoiesisLeukemia & Lymphoma, 1990